Did you know?

ChinaBio® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.  

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

  Email address:
   

Xiangxue Approved to Start China Trial of T-Cell Therapy for Solid Tumors

publication date: Mar 21, 2019

Guangzhou Xiangxue Life Sciences (XLifeSc), a subsidiary of Xiangxue Pharmaceutical, was approved by China's NMPA to start clinical studies of its T-cell receptor Affinity Enhanced Specific T-cell (TAEST) therapy in patients with solid tumors. Earlier, XLifeSc announced positive results from a small pilot study of the TAEST thrapy in China. Xiangxue in-licensed the therapy from Athenex, a New York state biopharma. The two companies jointly formed Axis Therapeutics, which owns global rights (ex-China) to the TAEST therapy. More details....

Stock Symbols: (SHA: 300147) (NSDQ: ATNX)

Share this with colleagues:



Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.


 

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

ChinaBio® News

Greg Scott BIO-Europe Interview
Greg Scott Interviewed at BIO-Europe Spring

How to bring your China assets to China in 8 minutes

Greg Scott Mendelspod Interview
"Mr. Bio in China."
Mendelspod Interview

Multinational pharma held to a higher standard in China

Partner Event
November 2-3, 2023 | Shanghai
November 7-8, 2023 | Digital